Topic
Topic
A 48-week real-world retrospective study on Springer Nature Link tracks lebrikizumab in atopic dermatitis patients who switched from dupilumab or tralokinumab. Effectiveness data pending full publica…
A peer-reviewed paper on Springer Nature Link examines cutaneous T-cell lymphoma in adult atopic dermatitis patients treated with…
A Frontiers pharmacovigilance study applies FAERS disproportionality analysis to tralokinumab adverse events in atopic dermatitis…
LEO Pharma presented new tralokinumab data at EADV 2026 on real-world outcomes and quality of life in adults and adolescents with…
LEO Pharma used EADV 2026 to present real-world tralokinumab data on outcomes and quality of life in adults and adolescents with…
TRACE subgroup data presented at EADV 2026 show 79.2% of AD patients with three high-impact areas involved report fewer affected…
